Arbutus to participate in june investor conferences

Warminster, pa., june 02, 2022 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the company will participate in the following upcoming investor conferences taking place in new york:
ABUS Ratings Summary
ABUS Quant Ranking